#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Systemic scleroderma Adenocarcinoma gastric Alexander disease Spina bifida Short stature homeobox gene mutation Neurodegenerative disorder Leukodystrophy Oesophageal adenocarcinoma stage III Bile acid synthesis disorder Inflammatory myofibroblastic tumour Choroid melanoma Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Hyperinsulinaemic hypoglycaemia Myxoid liposarcoma Pemphigoid More trials…

    Learn about Rare Diseases

    Lennox-Gastaut syndrome – Treatment Chondrosarcoma – Diagnostics Ewing’s sarcoma recurrent – Trials in Disease Vascular malformation – Diagnostics Acute respiratory distress syndrome Proteus syndrome – Diagnostics Lysosomal storage disorder – Trials in Disease Ewing’s sarcoma – Basic Information Ehlers-Danlos syndrome Epidermolysis bullosa – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Remimazolam PRT3789 Inebilizumab Zongertinib Donepezil Hydrochloride Afatinib Epirubicin Hydrochloride Glimepiride Deferiprone Dabigatran Setmelanotide Obeticholic Acid Selexipag Benztropine Mesylate Furosemide Ph. Eur. Eplontersen ADS-019 Ceftriaxone Varenicline Cln-081 More therapies…

    Learn about Your Condition

    Stress urinary incontinence Urinary tract infection Bile acid synthesis disorder Cardiac failure Pseudoxanthoma elasticum Barrett's oesophagus PIK3CA-activated mutation Endolymphatic hydrops Cardiac ventricular thrombosis Type 2 diabetes mellitus Device related infection Escherichia infection Hypoxia Gastric cancer Abortion threatened More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2lg Bxeghpazn Do Suxzer Mfgzmedltoa Bc 1rrk Mrutavfhdy 1ctmdd Fkdsfm

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Doxorubicin
    • Capecitabine
    • Doxorubicin Hydrochloride, Liposomal
    Austria France Germany Greece Hungary Ireland +7

  • Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Bortezomib
    • Daratumumab
    Czechia France Germany The Netherlands Poland Spain

  • Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Adenocarcinoma pancreas
    Belgium France Germany The Netherlands Spain Sweden

  • Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • 7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
    France Italy Poland Spain

  • Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Docetaxel
    France

  • Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Myelofibrosis
    Investigated Drugs:
    • 2-(3-(3,5-Dimethyltriazol-4-Yl)-5-((S)-Oxan-4-Yl(Phenyl)Methyl)Pyrido(3,2-B)Indol-7-Yl)Propan-2-Ol
    • Fedratinib
    • Ruxolitinib
    France Germany Greece Italy Poland Romania +1

  • Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Nivolumab
    Austria Belgium Denmark France Germany Greece +7

  • Study on Adding Ipilimumab to Atezolizumab and Bevacizumab for Patients with Liver Cancer Receiving First-Line Treatment

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Hepatic cancer
    Investigated Drugs:
    • Atezolizumab
    • Bevacizumab
    • Ipilimumab
    France

  • Study of Tolinapant with Decitabine and Cedazuridine for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

    Not recruiting

    1 1 1
    Investigated Drugs:
    • Tolinapant Lactate
    • Cedazuridine
    • Decitabine
    France Hungary Italy Poland Spain

  • Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Zadavotide Guraxetan
    • Piflufolastat (18F)
    • Abiraterone Acetate
    France Italy Spain
Previous Page
1 … 36 37 38 39 40 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!